Fujian Haixi New Drug Creation Co., Ltd. engages in the research and development, manufacture, and sale of pharmaceutical products. The company is headquartered in Fuzhou, Fujian. The company went IPO on 2025-10-20. The Company’s main products include Anbili, Haihuitong, Ruiantuo and Saixifu. The Company’s products are mainly used in digestive system diseases, cardiovascular system diseases, endocrine system diseases, nervous system diseases, inflammatory diseases, oncology, ophthalmology, respiratory diseases and others. The firm mainly operates its businesses in the domestic market.
02637.HK stock price ended at $161.5 on 목요일, after rising 3.59%
On the latest trading day Jan 15, 2026, the stock price of 02637.HK rose by 3.59%, climbing from $155.80 to $161.50. During the session, the stock saw a volatility of 3.85%, with prices oscillating between a daily low of $155.70 and a high of $161.70. Notably, trading volume dropped by 38.3K shares on the last day despite the price increase, which may signal a potential uptick in risk in the near term. A total of 108.5K shares were traded, equating to a market value of approximately $12.7B.
02637.HK 기술적 시그널
기술적 시그널 요약
구매 신호 5
중립 신호 0
매도 신호 2
Strong Sell
Sell
Neutral
Buy
Strong Buy
02637.HK은 현재 5개의 매수 신호와 2개의 매도 신호를 보이고 있습니다. 이 주식은 04:00 PM 이후로 상승 추세 상태에 있으며, 이 기간 동안 총 가격 변동률은 3.59%입니다. 전반적으로 기술적 지표들은 중기적으로 Buy 전망을 나타내고 있습니다.
02637.HK에 대한 강세/약세 신호
이동평균, RSI, MACD, 거래량 등 핵심 지표를 분석하여 02637.HK 의 강세/약세 시그널을 생성합니다. 이 인사이트를 활용해 더 현명한 투자 결정을 내리세요.